Skip to main content
OpenTrials
Completed

NCT Number: NCT02258776

The Effect of Pomegranate on Aging and Inflammation of the Skin

The purpose of this study is to determine the efficacy of pomegranate extract and pomegranate juice on skin inflammation and aging. The information gained from this study may lead to the development of a pomegranate product that can decrease the effects of aging, inflammation and harmful bacteria on the skin.

In this study, two pomegranate products (extract and juice) will be compared with a placebo, a study product that looks like pomegranate extract, but contains no active ingredients.

Completed

Looking for future studies?

Notify Me

Key information

Age range

30 year–45 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

UCLA Center for Human Nutrition

Los Angeles, California, 90095, United States

About this study

Pomegranate (Punica granatum L.) is grown commercially in the Near East, India, Spain, Israel and the United States (California) where it is of significant economic importance1. Pomegranate fruits and products, including juice, tea, wine and extracts are widely consumed and recognized for their health benefits. Pomegranate (Punica granatum L.) fruit possesses strong antioxidant, anti-inflammatory and antiproliferative properties. In recent years, most health advantages of pomegranate have been attributed to the presence of ellagitannins, mainly punicalagins and ellagic acid. Punicalagin is unique to pomegranate and is part of a family of ellagitannins. The ellagitannins are hydrolyzed to ellagic acid in the gut, and further metabolized by the colon microflora to form urolith A and B. Investigations using pure bacterial cultures have shown that pomegranate by-products and punicalagins significantly inhibited the growth of pathogenic Escherichia coli, Pseudomonas aeruginosa, clostridia and Staphylococcus aureus.

Oral feeding of pomegranate fruit extract to mice afforded protection to mouse skin against the adverse effects of ultraviolet-B (UVB) radiation by modulating UVB-induced signaling pathways.5 Hydroalcoholic extract based-ointment from pomegranate was reported improving wound healing in vivo. Pomegranate ellagitannins have been demonstrated to have antimicrobial activity. Punicalagin is unique to pomegranate and is part of a family of ellagitannins. The ellagitannins are hydrolyzed to ellagic acid in the gut, and further metabolized by the colon microflora to form urolith A and B. Investigations using pure bacterial cultures have shown that pomegranate by-products and punicalagins significantly inhibited the growth of pathogenic Escherichia coli, Pseudomonas aeruginosa, clostridia and Staphylococcus aureus.

Pomegranate Extract (POMx) is made from pomegranate fruit as a byproduct of pomegranate juice (PJ) production. A second pressing of the fruit liberates a complex mixture of hydrolysable polyphenolic compounds normally ingested with pomegranate juice, and these are purified by spray drying. POMx powder is encapsulated for oral administration, with each capsule containing 1,000 mg of pomegranate polyphenols. The present study will determine whether a pomegranate product (POMx or PJ) can decrease skin photoaging, inflammation and skin pathogenic bacteria.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 30-45 years or older, female and any racial/ethnic group
  • Subjects must understand and sign the informed consent prior to participation
  • Subjects must be in generally good health
  • Subjects must be able and willing to comply with the requirements of the protocol.

Exclusion criteria

  • Oral or topical retinoid use within twelve months of entry into the study
  • Non-compliant subjects
  • Taking any antibiotics or other medication or dietary supplements regularly
  • Subjects with a significant medical history or concurrent condition that the investigator(s) feel is not safe for the study
  • Subjects who cannot avoid excessive exposure to either natural or artificial sunlight.
  • Allergic to pomegranate products

Treatment and study plan

Pomegranate extract

Dietary Supplement

Pomegranate extract 1000mg will be taken 1/day for 12 weeks.

Pomegranate Juice

Dietary Supplement

Pomegranate juice 8oz will be consumed 1/day for 12 weeks.

Placebo

Dietary Supplement

Placebo will be taken 1/day for 12 weeks.

Primary outcomes

  1. Change in inflammatory markers between pomegranate extract and pomegranate juice versus placebo.

    Time frame: Baseline and 12 weeks

    Utilization of a two-sample t-test to compare the change in between the three groups

Secondary outcomes

  1. Linear mixed effects models to evaluate effect of treatment of time trends and demographic covariates

    Time frame: Baseline and 12 weeks

    Correlation between outcomes measures (e.g. between acne lesion count and skin microbiota) with mixed effects models

Sponsors and collaborators

Lead sponsor

University of California, Los Angeles

Other

Registry information

Official study title

Clinical Trial to Determine the Efficacy of Pomegranate for Skin Inflammation and Aging

Acronym: PomSkin

Important dates

Study start
2015
Primary completion
2017
Study completion
2017
First posted
Oct 7, 2014
Registry last updated
Mar 1, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.